Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early high-titer convalescent plasma for clinically vulnerable outpatients with mild COVID-19
NL-OMON51772Phase 3Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Convalescent plasma with Standard of care (2 arms). Started Oct 2022; status: active, not recruiting.
02
Drugs
COVID-19 convalescent plasma
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON51772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51772.